A Double-blind, Randomized, Placebo-controlled, Cross-over Study to Evaluate the Clinical Efficacy and Safety of Subcutaneous Administration of Human Plasma-derived C1-esterase Inhibitor in the Prophylactic Treatment of Hereditary Angioedema
Latest Information Update: 25 Jan 2023
At a glance
- Drugs Complement C1 inhibitor protein (Primary)
- Indications Hereditary angioedema
- Focus Registrational; Therapeutic Use
- Acronyms COMPACT
- Sponsors CSL Behring
- 28 Sep 2020 According to a CSL Behring media release, based on NCT02316353 and NCT01912456, the U.S. Food and Drug Administration (FDA) has approved an expanded indication for HAEGARDA (C1 Esterase Inhibitor Subcutaneous [Human]) for routine prophylaxis to prevent hereditary angioedema (HAE) attacks in patients 6 years of age and older.
- 20 May 2020 Results of pooled analysis assessing indirect comparison of Complement-C1-inhibitor-protein with Lanadelumab from two studies (HELP and CoMPACT) presented at the 25th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
- 21 Mar 2020 Results presented at the 121st Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics